Journal of Clinical Oncology
Articles in this Issue
Selective ASO-based JAK2 inhibitor for the treatment of hematological malignancies with JAK2 V617F mutation burden.
e14582 Background: Myeloproliferative disorders are clonal hematopoietic stem cell malignancies with cytokine independency or hypersensitivity. Due to dys...
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.
8615 Background: Pts with NSCLC harboring uncommon EGFR mutations generally have limited treatment options compared to those with...
The impact of iron deficiency anemia on long-term cardiovascular outcomes in breast cancer patients hospitalized with heart failure preserved ejection fraction: A propensity score–matched retrospective cohort study.
11041 Background: Breast cancer (BC) patients are at risk for iron deficiency anemia (IDA) due to the effects of chemotherapy on the bone marrow and becau...
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.
2510 Background: Circadian rhythms moderate immune cells trafficking and function over the 24 hours. This could account for the near doubling of overall s...
Tackling healthcare provider bias in care and research: A systematic review.
e23222 Background: Despite efforts in oncology to provide personalized and patient-centered care, clinical research lacks real-world representation leadin...
Effects of SGLT2i dapagliflozin in primary prevention of cardiotoxicity induced by short-term anthracycline and HER2 blocking agent therapy through inhibition of MyD88 and NLRP-3 pathways.
12023 Background: Anthracyclines, such as doxorubicin, and HER-2 blocking agents, like trastuzumab, are integral in breast cancer treatment but are associ...
Evaluating the benefit-risk balance of second-line therapies for HR+/HER2- metastatic breast cancer: A comparative analysis using ASCO VF and ESMO MCBS frameworks.
e13100 Background: The treatment landscape for HR+/HER2- metastatic breast cancer (mBC) is evolving at an unprecedented pace, necessitating a comprehensiv...
Assessing circadian rhythms and chemotherapy safety in remote patients with pancreatic ductal adenocarcinoma (PDAC) using a multidimensional digital platform (MultiDom, NCT04263948).
1650 Background: The disruption of circadian clocks is associated with reduced survival and treatment tolerability in cancer patients (pts). Here, real-ti...
Analysis of trends in race and gender disparities in the incidence of osteosarcoma, leiomyosarcoma, and Ewing sarcoma from 2000 to 2021.
e23516 Background: The incidence of osteosarcoma is 4 - 5.4 per 1 million people, leiomyosarcoma is 6 per 1 million people, and Ewing sarcoma is 1 per 1 m...
Diversity and representation in head and neck cancer trials following the 2010 Affordable Care Act.
e13827 Background: Racial and ethnic disparities across cancer subtypes are well documented. Clinical trials aim to raise the standard of care and push me...
Impact of gut microbiota (GM) and antibiotic (ATB) use on immunotherapy efficacy in patients with lung cancer (LC): Preliminary results from a prospective trial.
e20610 Background: LC is the leading cause of cancer death globally. Immune checkpoint inhibitors (ICI) have changed cancer treatment, but surpass resista...
Extended vs standard lymphadenectomy in patients of pancreatic head adenocarcinoma undergoing pancreatoduodenectomy: A systematic review and updated meta-analysis.
e16369 Background: Pancreatic Head Adenocarcinoma is treated by radical pancreaticoduodenenectomy, which also includes lymph node resection. Different RCT...
An update on the results of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma.
11554 Background: At the 2024 ASCO conference, we reported preliminary results on the efficacy and safety of IBI110 (anti-LAG-3 antibody) combined with si...
Neutrophil-to-lymphocyte ratio as a predictor of response and toxicity in T-cell engager therapy for solid tumors.
e14509 Background: The neutrophil-to-lymphocyte ratio (NLR) is a well-established predictive biomarker in patients receiving immune checkpoint inhibitors...
Efficacy and safety of envafolimab plus platinum-based chemotherapy as neoadjuvant therapy in resectable stage IIb-IIIb NSCLC: A single-arm, prospective, exploratory study.
e20510 Background: Multiple clinical trials have reported the striking benefit for PD-1/PD-L1 monoclonal antibody combined with chemotherapy neoadjuvant t...
Bladder cancer mortality among smokers: Trends and disparities in U.S. adults (1999–2023).
e16612 Background: Bladder cancer ranks as the 10th leading cause of cancer death in the United States (US), with over 81,000 new cases and 17,100 deaths...
Comparison of thrombocytopenia and splenomegaly in locally advanced rectal cancer patients receiving total neoadjuvant therapy with and without immunotherapy.
e15637 Background: Thrombocytopenia is one of the main adverse effects of oxaliplatin-based chemotherapy, probably due to the hepatic sinusoidal obstructi...
SIMRISE: A randomized phase III trial evaluating SIM0270 in combination with everolimus versus treatment of physician’s choice in patients with ER+/HER2- advanced breast cancer, previously treated with CDK4/6 inhibitors.
TPS1128 Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have demonstrated sustained benefits in the first-line treatmen...
Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).
5071 Background: Late-line mCRPC has shown poor outcomes as a result of disease heterogeneity, metastases in bone and viscera including liver, and limited...
Molecular residual disease (MRD) in solid tumors.
TPS3186 Background: Pragmatically designed clinical studies facilitate rapid accrual of representative populations by aligning research with routine care...
Comparative efficacy of PARP inhibitors in BRCA mutated HER2-negative breast cancer: A systematic review and network meta-analysis of randomized controlled trials.
e13162 Background: BRCA1/2 mutations impair homologous recombination repair, forcing cancer cells to rely on alternative DNA repair pathways, such as thos...
Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study.
e16229 Background: Anti-angiogenesis agents plus immune checkpoint inhibitors have been established as the first-line therapy for advanced hepatocellular...
Real-world impact of immunotherapy in metastatic uveal melanoma: A retrospective single-center study.
e21594 Background: There is no standard treatment for mUM and the efficacy and safety of IT and comparison with chemotherapy in real-world practice has no...
Real-world insights: Neoadjuvant KEYNOTE-522 regimen in triple-negative breast cancer patients with germline BRCA mutations.
e12618 Background: Triple-negative breast cancer (TNBC) is the most immunogenic subtype and is highly prevalent among patients (pts) with germline BRCA1/2...
Potential role of CCND1 in neoadjuvant therapy efficacy in esophageal squamous cell carcinoma and its relation to extracellular matrix.
e16136 Background: Radical surgical resection is a component in the treatment strategy for locally advanced esophageal squamous cell carcinoma (ESCC). Imm...